Table SIX. GSEA analyzed the significantly enriched pathways in the high-risk group and the low-risk group.

NAME	SIZE	ES	NES
ANTIGEN_PROCESSING_AND_PRESENTATION	79	0.7373	2.196
AUTOIMMUNE_THYROID_DISEASE	50	0.783	2.152
TYPE_I_DIABETES_MELLITUS	41	0.8216	2.1282
INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION	46	0.7719	2.0917
ALLOGRAFT_REJECTION	35	0.8822	2.0485
GRAFT_VERSUS_HOST_DISEASE	37	0.8673	2.0177
ASTHMA	28	0.7633	1.8908
PROTEASOME	44	0.7118	1.9421
CYTOSOLIC_DNA_SENSING_PATHWAY	55	0.6106	2.0385
PRIMARY_IMMUNODEFICIENCY	35	0.7579	2.0678
NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY	130	0.5564	1.9454
ECM_RECEPTOR_INTERACTION	84	-0.7078	-2.2036
BASAL_CELL_CARCINOMA	55	-0.6659	-2.1689
HEDGEHOG_SIGNALING_PATHWAY	56	-0.6466	-2.1461
AXON_GUIDANCE	128	-0.5392	-2.1089
FOCAL_ADHESION	199	-0.5519	-2.0616
TGF_BETA_SIGNALING_PATHWAY	85	-0.5339	-1.9963
MELANOGENESIS	101	-0.4842	-1.9
GAP_JUNCTION	89	-0.4659	-1.788
GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE	26	-0.6485	-1.9826
PATHWAYS_IN_CANCER	324	-0.4057	-1.7575
MELANOMA	71	-0.4904	-1.8415
ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC	74	-0.4924	-1.8067
WNT_SIGNALING_PATHWAY	149	-0.4827	-1.9242
GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDROITIN_SULFATE	22	-0.6736	-1.8309
DILATED_CARDIOMYOPATHY	90	-0.4759	-1.783